Esmolol
- Generic Name
- Esmolol
- Brand Names
- Brevibloc
- Drug Type
- Small Molecule
- Chemical Formula
- C16H25NO4
- CAS Number
- 81147-92-4
- Unique Ingredient Identifier
- MDY902UXSR
- Background
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decrea...
- Indication
For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.
- Associated Conditions
- Hypertension, Tachycardia, Abnormal ventricular rate, Heart rate abnormal
- Associated Therapies
- -
Changes in Cerebral Oxygenation and Cognitive Functions
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Zonguldak Bulent Ecevit University
- Target Recruit Count
- 40
- Registration Number
- NCT04948957
- Locations
- 🇹🇷
Zonguldak Bülent Ecevit University Medicine Faculty, Zonguldak, Kozlu, Turkey
Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Benha University
- Target Recruit Count
- 60
- Registration Number
- NCT04752111
- Locations
- 🇪🇬
Samar Rafik Mohamed Amin, Benha, Qalubia, Egypt
The Effect of Esmolol on Patients With Sepsis
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04537767
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
- Conditions
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT04356352
- Locations
- 🇺🇸
Wake Forest Health Sciences, Winston-Salem, North Carolina, United States
Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Kasr El Aini Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04306913
- Locations
- 🇪🇬
Kasr alainy medical school, Cairo, Egypt
Lidocaine Versus Esmolol for Optimizing Surgical Field Visibility
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 70
- Registration Number
- NCT04260685
- Locations
- 🇪🇬
Faculty of Medicine, Zagazig, Elsharkia, Egypt
Role of Intraoperative Beta Blocker for Morbid Obese Patients Undergoing Laparoscopic Bariatric Surgery
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT04086940
- Locations
- 🇪🇬
Ramymahrose, Cairo, Egypt
Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Hospital de Base
- Target Recruit Count
- 66
- Registration Number
- NCT03965442
- Locations
- 🇧🇷
Hospital de Base do Distrito Federal, Brasilia, DF, Brazil
Esmolol vs. Labetalol in Endoscopic Sinus Surgery
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-02-08
- Target Recruit Count
- 28
- Registration Number
- NCT03661346
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
The Effects of Lidocaine and Esmolol on Attenuation of Hemodynamic Response to Orotracheal Intubation
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Hospital de Base
- Target Recruit Count
- 80
- Registration Number
- NCT03612492
- Locations
- 🇧🇷
Hospital de Base do Distrito Federal, Brasilia, DF, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.